ABSTRACT
The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.
CLAIMS
1. A method of treating bone marrow injury in a subject who has not been administered cancer therapy, the method comprising contacting cells in the subject’s bone marrow with a therapeutically effective amount of a compound that inhibits the biological activity of Bcl-xL and Bcl-2 protein that is present in p16 positive senescent cells in the bone marrow, wherein the compound is selected from GX15-070 (obatoclax), gossypol (AT-101), apogossypolone, TW37, TM-1206, ABT-737, ABT-263 (navitoclax), WHEI539, and combinations thereof, whereby the compound selectively removes the senescent cells in comparison with non-senescent cells in the subject’s bone marrow, thereby delaying progression of the injury.